Literature DB >> 20158473

Epoxyeicosatrienoic acid analogs and vascular function.

V Sudhahar1, S Shaw, J D Imig.   

Abstract

Arachidonic acid metabolites, eicosanoids, are key contributors to vascular function and improper eicosanoid regulation contributes to the progression of cardiovascular diseases. Epoxyeicosatrienoic acids (EETs) are synthesized from arachidonic acid by epoxygenase enzymes to four regioisomers, 5,6-EET, 8,9-EET, 11,12-EET, and 14,15-EET. These EETs have interesting beneficial effects like vasodilation, anti-inflammation, and anti-platelet aggregation that could combat cardiovascular diseases. There is mounting evidence that each regioisomeric EET may have unique vascular effects and that the contribution of individual EETs to vascular function differs from organ to organ. Over the past decade EET analogs and antagonists have been synthesized to determine EET structure function relationships and define the contribution of each regioisomeric EET. A number of studies have demonstrated that EET analogs induce vasodilation, lower blood pressure and decrease inflammation. EET antagonists have also been used to demonstrate that endogenous EETs contribute importantly to cardiovascular function. This review will discuss EET synthesis, regulation and physiological roles in the cardiovascular system. Next we will focus on the development of EET analogs and what has been learned about their contribution to vascular function. Finally, the development of EET antagonists and how these have been utilized to determine the cardiovascular actions of endogenous epoxides will be discussed. Overall, this review will highlight the important knowledge garnered by the development of EET analogs and their possible value in the treatment of cardiovascular diseases.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20158473      PMCID: PMC2855336          DOI: 10.2174/092986710790827843

Source DB:  PubMed          Journal:  Curr Med Chem        ISSN: 0929-8673            Impact factor:   4.530


  81 in total

1.  Rat mesenteric arterial dilator response to 11,12-epoxyeicosatrienoic acid is mediated by activating heme oxygenase.

Authors:  David Sacerdoti; Massimo Bolognesi; Marco Di Pascoli; Angelo Gatta; John C McGiff; Michal Laniado Schwartzman; Nader G Abraham
Journal:  Am J Physiol Heart Circ Physiol       Date:  2006-06-23       Impact factor: 4.733

2.  Protein phosphatase 2A and Ca2+-activated K+ channels contribute to 11,12-epoxyeicosatrienoic acid analog mediated mesenteric arterial relaxation.

Authors:  Christiana Dimitropoulou; Lashondra West; Mary B Field; Richard E White; L Manmohan Reddy; John R Falck; John D Imig
Journal:  Prostaglandins Other Lipid Mediat       Date:  2006-11-07       Impact factor: 3.072

3.  Role of CYP epoxygenases in A2A AR-mediated relaxation using A2A AR-null and wild-type mice.

Authors:  Mohammed A Nayeem; Samuel M Poloyac; John R Falck; Darryl C Zeldin; Catherine Ledent; Dovenia S Ponnoth; Habib R Ansari; S Jamal Mustafa
Journal:  Am J Physiol Heart Circ Physiol       Date:  2008-09-19       Impact factor: 4.733

Review 4.  Cardiovascular therapeutic aspects of soluble epoxide hydrolase inhibitors.

Authors:  John D Imig
Journal:  Cardiovasc Drug Rev       Date:  2006

5.  Cytochrome P450 eicosanoids are activators of peroxisome proliferator-activated receptor alpha.

Authors:  Valerie Y Ng; Yong Huang; L Manmohan Reddy; John R Falck; Emil T Lin; Deanna L Kroetz
Journal:  Drug Metab Dispos       Date:  2007-04-12       Impact factor: 3.922

6.  Characterization of 14,15-epoxyeicosatrienoyl-sulfonamides as 14,15-epoxyeicosatrienoic acid agonists: use for studies of metabolism and ligand binding.

Authors:  Wenqi Yang; Blythe B Holmes; V Raj Gopal; R V Krishna Kishore; Bhavani Sangras; Xiu-Yu Yi; J R Falck; William B Campbell
Journal:  J Pharmacol Exp Ther       Date:  2007-02-27       Impact factor: 4.030

7.  Low Na intake suppresses expression of CYP2C23 and arachidonic acid-induced inhibition of ENaC.

Authors:  Peng Sun; Dao-Hong Lin; Tong Wang; Elisa Babilonia; Zhijian Wang; Yan Jin; Rowena Kemp; Alberto Nasjletti; Wen-Hui Wang
Journal:  Am J Physiol Renal Physiol       Date:  2006-07-18

8.  Soluble epoxide hydrolase gene deletion is protective against experimental cerebral ischemia.

Authors:  Wenri Zhang; Takashi Otsuka; Nobuo Sugo; Ardi Ardeshiri; Yazan K Alhadid; Jeffrey J Iliff; Andrea E DeBarber; Dennis R Koop; Nabil J Alkayed
Journal:  Stroke       Date:  2008-03-27       Impact factor: 7.914

9.  Activation of sphingosine kinase-1 mediates induction of endothelial cell proliferation and angiogenesis by epoxyeicosatrienoic acids.

Authors:  Guijun Yan; Shaoping Chen; Bei You; Jianxin Sun
Journal:  Cardiovasc Res       Date:  2008-01-10       Impact factor: 10.787

10.  Afferent arteriolar dilation to 11, 12-EET analogs involves PP2A activity and Ca2+-activated K+ Channels.

Authors:  John D Imig; Christiana Dimitropoulou; D Sudarshan Reddy; Richard E White; John R Falck
Journal:  Microcirculation       Date:  2008-02       Impact factor: 2.628

View more
  49 in total

1.  The protective effect of epoxyeicosatrienoic acids on cerebral ischemia/reperfusion injury is associated with PI3K/Akt pathway and ATP-sensitive potassium channels.

Authors:  You-Yang Qu; Mei-Yan Yuan; Yu Liu; Xing-Jun Xiao; Yu-Lan Zhu
Journal:  Neurochem Res       Date:  2014-11-04       Impact factor: 3.996

Review 2.  Targeting epoxides for organ damage in hypertension.

Authors:  John D Imig
Journal:  J Cardiovasc Pharmacol       Date:  2010-10       Impact factor: 3.105

Review 3.  Cytochrome P450 eicosanoids and cerebral vascular function.

Authors:  John D Imig; Alexis N Simpkins; Marija Renic; David R Harder
Journal:  Expert Rev Mol Med       Date:  2011-03-01       Impact factor: 5.600

Review 4.  Modulation of innate immunity of patients with Alzheimer's disease by omega-3 fatty acids.

Authors:  Milan Fiala; Gijs Kooij; Karen Wagner; Bruce Hammock; Matteo Pellegrini
Journal:  FASEB J       Date:  2017-04-18       Impact factor: 5.191

Review 5.  Cytochrome P450 and Lipoxygenase Metabolites on Renal Function.

Authors:  John D Imig; Md Abdul Hye Khan
Journal:  Compr Physiol       Date:  2015-12-15       Impact factor: 9.090

6.  Soluble epoxide hydrolase expression in a porcine model of arteriovenous graft stenosis and anti-inflammatory effects of a soluble epoxide hydrolase inhibitor.

Authors:  William G Sanders; Christophe Morisseau; Bruce D Hammock; Alfred K Cheung; Christi M Terry
Journal:  Am J Physiol Cell Physiol       Date:  2012-05-23       Impact factor: 4.249

7.  Cytochrome P450 2C24: Expression, Tissue Distribution, High-Throughput Assay, and Pharmacological Inhibition.

Authors:  Jun Yang; Melissa A VanAlstine; James G Phillips; Mark P Wentland; Lindsay B Hough
Journal:  Acta Pharm Sin B       Date:  2012-04       Impact factor: 11.413

8.  Soluble Epoxide Hydrolase Deficiency or Inhibition Attenuates MPTP-Induced Parkinsonism.

Authors:  Xiaocui Qin; Qiaoqi Wu; Lifang Lin; Aimin Sun; Shuhu Liu; Xiaowen Li; Xiong Cao; Tianming Gao; Pengcheng Luo; Xinhong Zhu; Xuemin Wang
Journal:  Mol Neurobiol       Date:  2014-08-17       Impact factor: 5.590

Review 9.  Epoxyeicosatrienoic acids, hypertension, and kidney injury.

Authors:  John D Imig
Journal:  Hypertension       Date:  2015-01-12       Impact factor: 10.190

Review 10.  Epoxyeicosatrienoic Acids and 20-Hydroxyeicosatetraenoic Acid on Endothelial and Vascular Function.

Authors:  J D Imig
Journal:  Adv Pharmacol       Date:  2016-05-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.